International differences in lung cancer survival by sex, histological type and stage at diagnosis: An ICBP SURVMARK-2 Study
Thorax — Araghi M, Fidler-Benaoudia M, Arnold M, et al. | July 20, 2021
This study was intended to evaluate the international differences in lung cancer survival by sex, histological type, and stage at diagnosis. Researchers enrolled a total of 236,114 non-small cell lung cancer (NSCLC) and 43,167 small cell lung cancer cases diagnosed during 2010–2014 in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK in the analyses. They calculated one-year and 3-year age-standardized net survival by gender, histological type, stage, and country. The results of this study demonstrate that the distribution of stage at diagnosis among lung cancer cases differed by gender, histological subtype, and country, which may partly explain observed survival differences. The study found survival differences within stages, implying that quality of treatment, healthcare system factors, and prevalence of comorbid conditions may also influence survival. Moreover, other possible explanations include variations in data collection practice, as well as differences in histological verification, staging, and coding across jurisdictions.
Read the full article on Thorax